Syed Abbas Ali

TL;DR: The first-in-humans clinical trial of chimeric antigen receptor (CAR) T cells targeting BCMA demonstrates antimyeloma activity of CAR-BCMA T cells.

TL;DR: CAR-BCMA T cells had substantial activity against heavily treated relapsed/refractory MM and should encourage additional development of CAR T-cell therapies for MM.

TL;DR: Increasing total body irradiation from 200 cGy to 400 cGy substantially reduced graft failure while maintaining the safety of haploidentical bone marrow transplantation with post-transplantation cyclophosphamide.

TL;DR: A Phase 1, 3+3 dose escalation trial is being conducted in patients with r/r MM to assess the safety and efficacy of P-BCMA-101, designed to increase efficacy while minimizing toxicity through reduced immunogenicity, lack of tonic signaling, a safety switch, and a product comprised predominantly of early memory T cells that are effectively all CAR-positive.

TL;DR: Findings provide proof of concept that adoptive immunotherapy using ex vivo expanded CD38KO NK cells has the potential to boost DARA activity in MM.